Human Agonistic Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2 Induces Cytotoxicity and Apoptosis in Prostate Cancer and Bladder Cancer Cells

Urology

Volumn 69, Issue 2, 2007, Pages 395-401

  Shimada, Osamu ^a,b   Wu, Xiuxian ^a   Jin, Xinghua ^a   Abdel Muneem Nouh, Mohammed Ahmed ^a   Fiscella, Michele ^c   Albert, Vivian ^c   Matsuda, Tadashi ^b   Kakehi, Yoshiyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c Antibody Development Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HGS ETR2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CELL SURFACE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC VALUE; DRUG EFFICACY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MALE; PROBABILITY; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 33847069661     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.12.007     Document Type: Article

References (32)

1. Griffith T.S., and Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10 (1998) 559-563
2. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
3. Van Valen F., Fulda S., Truckenbrod B., et al. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 88 (2000) 252-259
4. Hao C., Song J.H., Hsi B., et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64 (2004) 8502-8506
5. Wu X.X., Kakehi Y., Mizutani Y., et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 104 (2003) 409-417
6. Pan G., Ni J., Wei Y.F., et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
7. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
8. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
9. Ashkenazi A., and Dixit V.M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11 (1999) 255-260
10. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
11. Degli-Esposti M.A., Dougall W.C., Smolak P.J., et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
12. Ichikawa K., Liu W., Fleck M., et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171 (2003) 1061-1069
13. Miranda-Carus M.E., Balsa A., Benito-Miguel M., et al. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 50 (2004) 2786-2793
14. Ichikawa K., Liu W., Zhao L., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7 (2001) 954-960
15. Zeng Y., Wu X.X., Fiscella M., et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 28 (2006) 421-430
16. Pukac L., Kanakaraj P., Humphreys R., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92 (2005) 1430-1441
17. Wu X.X., Mizutani Y., Kakehi Y., et al. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60 (2000) 2912-2918
18. Wu X.X., Kakehi Y., Mizutani Y., et al. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 19 (2001) 19-24
19. Wu X.X., Ogawa O., and Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by [scap]l[r]-buthionine sulfoximine. Int J Oncol 24 (2004) 1485-1497
20. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 (2002) 19-30
21. Chuntharapai A., Dodge K., Grimmer K., et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166 (2001) 4891-4898
22. Takeda K., Yamaguchi N., Akiba H., et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199 (2004) 437-448
23. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 (2003) 17-22
24. Amantana A., London C.A., Iversen P.L., et al. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3 (2004) 699-707
25. Johnson T.R., Stone K., Nikrad M., et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22 (2003) 4953-4963
26. Wang C.Y., Mayo M.W., Korneluk R.G., et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
27. Liu Q., Hilsenbeck S., and Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 (2003) 4078-4087
28. LaVallee T.M., Zhan X.H., Johnson M.S., et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63 (2003) 468-475
29. Shigeno M., Nakao K., Ichikawa T., et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22 (2003) 1653-1662
30. Griffith T.S., Rauch C.T., Smolak P.J., et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162 (1999) 2597-2605
31. Menoret E., Gomez-Bougie P., Geffroy-Luseau A., et al. Mcl-1L cleavage is involved in TRAIL-R1 and TRAIL-R2 mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAb in myeloma cells. Blood 108 (2006) 1346-1352
32. Georgakis G.V., Li Y., Humphreys R., et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130 (2005) 501-510